PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
799.80%
Cash & equivalents growing 799.80% while GNPX's declined -4.13%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
799.80%
Below half of GNPX's -4.13%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
700.88%
≥ 1.5x GNPX's 0.52%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-9.67%
1.25-1.5x GNPX's -8.73%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.93%
≥ 1.5x GNPX's -2.77%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
569.03%
≥ 1.5x GNPX's 0.44%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
1.26%
Less than half of GNPX's -71.50%. David Dodd sees a more disciplined AP approach or lower volume.
-42.54%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
5.04%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-1.15%
Less than half of GNPX's -65.61%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-2.99%
Less than half of GNPX's -65.61%. David Dodd sees far fewer liability expansions relative to competitor.
-92.57%
Less than half of GNPX's 17.60%. David Dodd sees fewer share issuances vs. competitor.
-2.16%
Below half GNPX's -9.50%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1581.26%
≥ 1.5x GNPX's 2.37%. David Dodd sees stronger capital base growth than competitor.
569.03%
≥ 1.5x GNPX's 0.44%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-1028.99%
Less than half of GNPX's 4.13%. David Dodd sees better deleveraging or stronger cash buildup than competitor.